 CureVac BV NASDAQ: CVAC said its first-generation COVID-19 vaccine candidate had passed its first interim analysis, but it was not yet ready to share efficacy data. The company said an independent Data Safety Monitoring Board found no safety concerns for the vaccine, dubbed CV2CoV. 